Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review

References

• Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983;12(6):418–424. PMID: 6325356. doi:10.1016/s0300-9785(83)80033-7
   PubMedGoogle Scholar
• Tumban E. A current update on human papillomavirus-associated head and neck cancers. Viruses. 2019;11(10):922. PMID: 31600915; PMCID: PMC6833051. doi:10.3390/v11100922
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541–550. PMID: 19190158; PMCID: PMC3051410. doi:10.1158/1055-9965.EPI-08-0347
   PubMed Web of Science ®Google Scholar
• Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–1331. PMID: 25439690. doi:10.1016/S1470-2045(14)70471-1
   PubMed Web of Science ®Google Scholar
• Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–282. PMID: 29497144. doi:10.1038/nrc.2018.11
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. PMID: 30207593. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122(3):306–314. PMID: 31708575; PMCID: PMC7000688. doi:10.1038/s41416-019-0602-7
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. PMID: 28369882; PMCID: PMC5520228. doi:10.1002/ijc.30716
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403. PMID: 26823521. doi:10.1093/jnci/djv403
   PubMedGoogle Scholar
• de Sanjosé S, Serrano B, Tous S, et al. Burden of Human Papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019;2(4):ky045. PMID: 31360870; PMCID: PMC6649711. doi:10.1093/jncics/pky045
   Web of Science ®Google Scholar
• Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol. 2019;37(18):1538–1546. PMID: 31026209; PMCID: PMC6599405. doi:10.1200/JCO.19.00370
   PubMed Web of Science ®Google Scholar
• Mahal BA, Catalano PJ, Haddad RI, et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1660–1667. PMID: 31358520. doi:10.1158/1055-9965.EPI-19-0038
   PubMed Web of Science ®Google Scholar
• D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–1956. PMID: 17494927. doi:10.1056/NEJMoa065497
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fakhry C, D’Souza G. Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020–2045. JAMA Oncol. 2021;7(10):e212907. PMID: 34473210; PMCID: PMC8414358. doi:10.1001/jamaoncol.2021.2907
   PubMed Web of Science ®Google Scholar
• Aboagye E, Agyemang-Yeboah F, Duduyemi BM, Obirikorang C. Human papillomavirus detection in head and neck squamous cell carcinomas at a tertiary hospital in Sub-Saharan Africa. ScientificWorldJournal. 2019;2019:2561530. PMID: 31061653; PMCID: PMC6466863. doi:10.1155/2019/2561530
   PubMedGoogle Scholar
• Bulane A, Goedhals D, Seedat RY, Goedhals J, Burt F. Human papillomavirus DNA in head and neck squamous cell carcinomas in the Free State, South Africa. J Med Virol. 2020;92(2):227–233. PMID: 31347711. doi:10.1002/jmv.25556
   PubMed Web of Science ®Google Scholar
• Graham SV, Faizo AAA. Control of human papillomavirus gene expression by alternative splicing. Virus Res. 2017;231:83–95. PMID: 27867028; PMCID: PMC5335905. doi:10.1016/j.virusres.2016.11.016
   PubMed Web of Science ®Google Scholar
• Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445(1–2):138–168. PMID: 23731972; PMCID: PMC3783579. doi:10.1016/j.virol.2013.04.013
   PubMed Web of Science ®Google Scholar
• Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–114. PMID: 2983228. doi:10.1038/314111a0
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–1136. PMID: 2175676. doi:10.1016/0092-8674(90)90409-8
   PubMed Web of Science ®Google Scholar
• Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem. 2004;279(24):25729–25744. PMID: 15073179. doi:10.1074/jbc.M401172200
   PubMed Web of Science ®Google Scholar
• Shah M, Anwar MA, Park S, Jafri SS, Choi S. In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response. Sci Rep. 2015;5:13446. PMID: 26289783; PMCID: PMC4542336. doi:10.1038/srep13446
   PubMed Web of Science ®Google Scholar
• Li S, Labrecque S, Gauzzi MC, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 1999;18(42):5727–5737. PMID: 10523853. doi:10.1038/sj.onc.1202960
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen R. Telomerase Induction in HPV Infection and Oncogenesis. Viruses. 2017;9(7):180. PMID: 28698524; PMCID: PMC5537672. doi:10.3390/v9070180
   PubMed Web of Science ®Google Scholar
• Stephen JK, Divine G, Chen KM, Chitale D, Havard S, Worsham MJ. Significance of p16 in site-specific HPV positive and HPV negative head and neck squamous cell carcinoma. Cancer Clin Oncol. 2013;2(1):51–61. PMID: 23935769; PMCID: PMC3736998. doi:10.5539/cco.v2n1p51
   PubMedGoogle Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–560. PMID: 20592731. doi:10.1038/nrc2886
   PubMed Web of Science ®Google Scholar
• Hasan UA, Zannetti C, Parroche P, et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med. 2013;210(7):1369–1387. PMID: 23752229; PMCID: PMC3698525. doi:10.1084/jem.20122394
   PubMed Web of Science ®Google Scholar
• Michaud DS, Langevin SM, Eliot M, et al. High-risk HPV types and head and neck cancer. Int J Cancer. 2014;135(7):1653–1661. PMID: 24615247; PMCID: PMC4107082. doi:10.1002/ijc.28811
   PubMed Web of Science ®Google Scholar
• Gutierrez-Xicotencatl L, Pedroza-Saavedra A, Chihu-Amparan L, Salazar-Piña A, Maldonado-Gama M, Esquivel-Guadarrama F. Cellular functions of HPV16 E5 oncoprotein during oncogenic transformation. Mol Cancer Res. 2021;19(2):167–179. PMID: 33106372. doi:10.1158/1541-7786.MCR-20-0491
   PubMed Web of Science ®Google Scholar
• Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–789. PMID: 20451455; PMCID: PMC5242182. doi:10.1016/S1470-2045(10)70017-6
   PubMed Web of Science ®Google Scholar
• Gupta I, Ghabreau L, Al-Thawadi H, et al. Co-incidence of human papillomaviruses and Epstein-Barr virus is associated with high to intermediate tumor grade in human head and neck cancer in Syria. Front Oncol. 2020;10:1016. PMID: 32974123; PMCID: PMC7468388. doi:10.3389/fonc.2020.01016
   PubMed Web of Science ®Google Scholar
• Al-Thawadi H, Gupta I, Jabeen A, et al. Co-presence of human papillomaviruses and Epstein-Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell Int. 2020;20:361. PMID: 32774155; PMCID: PMC7397600. doi:10.1186/s12935-020-01348-y
   PubMed Web of Science ®Google Scholar
• Dunne EF, Markowitz LE, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). CDC grand rounds: reducing the burden of HPV-associated cancer and disease. MMWR Morb Mortal Wkly Rep. 2014;63(4):69–72. PMID: 24476977; PMCID: PMC4584896.
   PubMed Web of Science ®Google Scholar
• Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7–8):1920–1928. PMID: 31050595; PMCID: PMC6746516. doi:10.1080/21645515.2019.1600985
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR–05): 1–30. PMID: 25167164.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al.; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–1255. PMID: 16631880. doi:10.1016/S0140-6736(06)68439-0
   PubMed Web of Science ®Google Scholar
• Dundar Y, Eldem I, Schwartz C, et al. Screening awareness of HPV-related oropharyngeal cancers and attitudes and concerns towards HPV vaccination among parents: HPV and oropharyngeal cancer. J Cancer Educ. 2022;37(4):1152–1160. PMID: 33411252. doi:10.1007/s13187-020-01932-w
   PubMed Web of Science ®Google Scholar
• Parsel SM, Barton BM, Beatty S, Friedlander PL. Knowledge gaps among patients and providers in HPV-related oropharyngeal cancer: a systematic review. Otolaryngol Head Neck Surg. 2020;162(5):612–621. PMID: 32122242. doi:10.1177/0194599820908596
   PubMed Web of Science ®Google Scholar
• Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? Oral Oncol. 2021;115:105168. PMID: 33730628. doi:10.1016/j.oraloncology.2020.105168
   PubMed Web of Science ®Google Scholar
• Handisurya A, Schellenbacher C, Haitel A, Senger T, Kirnbauer R. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer. 2016;114(4):409–416. PMID: 26867163; PMCID: PMC4815771. doi:10.1038/bjc.2015.462
   PubMed Web of Science ®Google Scholar
• Tang J, Li M, Zhao C, et al. Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials. Viruses. 2022;14(2):239. PMID: 35215833; PMCID: PMC8874761. doi:10.3390/v14020239
   PubMed Web of Science ®Google Scholar
• Rosales R, López-Contreras M, Rosales C, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther. 2014;25(12):1035–1049. PMID: 25275724; PMCID: PMC4270165. doi:10.1089/hum.2014.024
   PubMed Web of Science ®Google Scholar
• McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(5):441–447. PMID: 24652023. doi:10.1001/jamaoto.2014.141
   PubMed Web of Science ®Google Scholar
• Cantrell SC, Peck BW, Li G, Wei Q, Sturgis EM, Ginsberg LE. Differences in imaging characteristics of HPV-positive and HPV-Negative oropharyngeal cancers: a blinded matched-pair analysis. AJNR Am J Neuroradiol. 2013;34(10):2005–2009. PMID: 23660291; PMCID: PMC3951375. doi:10.3174/ajnr.A3524
   PubMed Web of Science ®Google Scholar
• Stenmark MH, Shumway D, Guo C, et al. Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States. Laryngoscope. 2017;127(10):2270–2278. PMID: 28304083; PMCID: PMC6615732. doi:10.1002/lary.26566
   PubMed Web of Science ®Google Scholar
• Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer. 1997;79(3):595–604. PMID: 9028373. doi:10.1002/(sici)1097-0142(19970201)79:3<595::aid-cncr24>3.0.co;2-y
   PubMed Web of Science ®Google Scholar
• Sastre-Garau X, Harlé A. Pathology of HPV-associated head and neck carcinomas: recent data and perspectives for the development of specific tumor markers. Front Oncol. 2020;10:528957. PMID: 33312940; PMCID: PMC7701329. doi:10.3389/fonc.2020.528957
   PubMed Web of Science ®Google Scholar
• Gameiro SF, Ghasemi F, Barrett JW, et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. Oncoimmunology. 2018;7(10):e1498439. PMID: 30288365; PMCID: PMC6169583. doi:10.1080/2162402X.2018.1498439
   PubMed Web of Science ®Google Scholar
• Mirghani H, Casiraghi O, Amen F, et al. Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Mod Pathol. 2015;28(12):1518–1527. PMID: 26403782. doi:10.1038/modpathol.2015.113
   PubMed Web of Science ®Google Scholar
• Frederiksen JG, Channir HI, Larsen MHH, et al. Long-term survival outcomes after primary transoral robotic surgery (TORS) with concurrent neck dissection for early-stage oropharyngeal squamous cell carcinoma. Acta Otolaryngol. 2021;141(7):714–718. PMID: 34191671. doi:10.1080/00016489.2021.1939147
   PubMed Web of Science ®Google Scholar
• Cannon RB, Houlton JJ, Patel S, et al. Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS). Oral Oncol. 2018;86:296–300. PMID: 30409315. doi:10.1016/j.oraloncology.2018.10.001
   PubMed Web of Science ®Google Scholar
• Meccariello G, Montevecchi F, D’Agostino G, et al. Trans-oral robotic surgery for the management of oropharyngeal carcinomas: a 9-year institutional experience. Acta Otorhinolaryngol Ital. 2019;39(2):75–83. PMID: 31097824; PMCID: PMC6522856. doi:10.14639/0392-100X-2199
   PubMed Web of Science ®Google Scholar
• Carey RM, Brody RM, Shimunov D, et al. Locoregional recurrence in p16-positive oropharyngeal squamous cell carcinoma after TORS. Laryngoscope. 2021;131(12):E2865–E2873. PMID: 34076275. doi:10.1002/lary.29659
   PubMed Web of Science ®Google Scholar
• Moore EJ, Van Abel KM, Price DL, et al. Transoral robotic surgery for oropharyngeal carcinoma: surgical margins and oncologic outcomes. Head Neck. 2018;40(4):747–755. PMID: 29327784. doi:10.1002/hed.25055
   PubMed Web of Science ®Google Scholar
• O’Hara J, Warner L, Fox H, et al. Primary transoral robotic surgery +/- adjuvant therapy for oropharyngeal squamous cell carcinoma-A large observational single-centre series from the United Kingdom. Clin Otolaryngol. 2021;46(5):1005–1012. PMID: 33754476. doi:10.1111/coa.13769
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578. PMID: 16467544. doi:10.1056/NEJMoa053422
   PubMed Web of Science ®Google Scholar
• Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer. Drug Resist Updat. 2018;40:13–16. PMID: 30466712. doi:10.1016/j.drup.2018.09.001
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. PMID: 27247226. doi:10.1016/S1470-2045(16)30066-3
   PubMed Web of Science ®Google Scholar
• Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II study. J Clin Oncol. 2017;35(14):1542–1549. PMID: 28328302; PMCID: PMC5946724. doi:10.1200/JCO.2016.70.1524
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, et al.; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–167. PMID: 30509740. doi:10.1016/S0140-6736(18)31999-8
   PubMed Web of Science ®Google Scholar
• Zech HB, Berger J, Mansour WY, et al. Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer. Radiother Oncol. 2022;168:138–146. PMID: 35093407. doi:10.1016/j.radonc.2022.01.017
   PubMed Web of Science ®Google Scholar
• Leeman JE, Li Y, Bell A, et al. Human papillomavirus 16 promotes microhomology-mediated end-joining. Proc Natl Acad Sci U S A. 2019;116(43):21573–21579. PMID: 31591214; PMCID: PMC6815166. doi:10.1073/pnas.1906120116
   PubMed Web of Science ®Google Scholar
• Liu Q, Ma L, Jones T, et al. Subjugation of TGFβ signaling by human papilloma virus in head and neck squamous cell carcinoma Shifts DNA repair from homologous recombination to alternative end joining. Clin Cancer Res. 2018;24(23):6001–6014. PMID: 30087144. doi:10.1158/1078-0432.CCR-18-1346
   PubMed Web of Science ®Google Scholar
• Marur S, Li S, Cmelak AJ, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group. J Clin Oncol. 2017;35(5):490–497. PMID: 28029303; PMCID: PMC5455313. doi:10.1200/JCO.2016.68.3300
   PubMed Web of Science ®Google Scholar
• Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, Phase 2 study. Lancet Oncol. 2017;18(6):803–811. PMID: 28434660; PMCID: PMC6488353. doi:10.1016/S1470-2045(17)30246-2
   PubMed Web of Science ®Google Scholar
• Lassen P, Eriksen JG, Krogdahl A, et al.; Danish Head and Neck Cancer Group (DAHANCA). The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011;100(1):49–55. PMID: 21429609. doi:10.1016/j.radonc.2011.02.010
   PubMed Web of Science ®Google Scholar
• Chen L, Riaz N, Lee N, McBride S. Current considerations for radiotherapy in HPV-associated head and neck cancer. J Surg Oncol. 2021;124(6):945–951. PMID: 34617275. doi:10.1002/jso.26689
   PubMed Web of Science ®Google Scholar
• Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002). J Clin Oncol. 2021;39(9):956–965. PMID: 33507809; PMCID: PMC8078254. doi:10.1200/JCO.20.03128
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76(5):1333–1338. PMID: 19540060; PMCID: PMC2846217. doi:10.1016/j.ijrobp.2009.04.011
   PubMed Web of Science ®Google Scholar